ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0099

Interleukin 6 Concentration in Synovial Fluid of Patients with Different Types of Arthritis

Aleksandra Bukina1 and Anna Mihailova1, 1Rigas Stradins university, Riga, Latvia

Meeting: ACR Convergence 2020

Keywords: Inflammation, Interleukins, Osteoarthritis, Synovitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Persistent synovitis without known markers such as rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) as well as without genetic markers as HLAB27 is not uncommon. It is valuable to determine the presents of chronic inflammation and differentiate with age-related changes, what are especially relevant for middle-aged patients with mono- or oligo- arthritis, when dilemma to start disease modifying drugs for inflammatory disease often is present. Interleukin 6 (IL6) is a pleiotropic pro-inflammatory cytokine, which play significant role in the chronic inflammation and autoimmunity. IL6 concentration in synovial fluid was studied in different types of arthritis. The aim of present study to compare concentration of IL6 in synovial fluid in patients with known type of arthritis.

Methods: Synovial fluid was obtained from one hundred one patients with chronic synovitis, mostly from knee joints. IL6 concentration was determined by immunochemical luminescence method.

Results: The median IL6 concentration in synovial fluid in patients with osteoarthritis (OA) was 138.0 pg/ml (IQR 43.4 to 296.0) without any significant differences in primary and secondary osteoarthritis. In inflammatory arthropathies median IL6 level was 2194.0 pg/ml (IQR 1254.0 to 8625.0). Median IL6 concentration in patients with rheumatoid arthritis (RA) was 2516.5 pg/ml, (IQR 1136.0 to 25058.0). There was not significant differences found between seronegative and seropositive RA groups. In reactive arthritis (ReA) median IL6 level was 2281.0 pg/ml (IQR 1392.0 to 8652.0); psoriatic arthritis (PsA) – 1964.0 pg/ml (IQR 754.0 to 7300.0) and ankylosing spondylitis (AS) – 2776.0 pg/ml (IQR 514.7, 3944.0). In group of 19 patients with negative RF, ACPA and HLAB27 inflammatory arthritis (IA) median IL6 level was 2163.0 pg/ml (IQR 822.0 to 7875.0). The pairwise comparison of diagnosis by Kruskal-Wallis Test show statistically significant difference in OA and RA, OA and ReA, OA and PsA groups, p< 0.0001.

Conclusion: IL6 detection in the synovial fluid is useful in arthritis evaluation. The results show that IL6 level over 1000 pg/ml suggest diagnosis of inflammatory arthritis.

IL-6 concentration in patients with osteoarthritis

IL-6 concentration in patient with inflammatory arthritis


Disclosure: A. Bukina, None; A. Mihailova, None.

To cite this abstract in AMA style:

Bukina A, Mihailova A. Interleukin 6 Concentration in Synovial Fluid of Patients with Different Types of Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/interleukin-6-concentration-in-synovial-fluid-of-patients-with-different-types-of-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interleukin-6-concentration-in-synovial-fluid-of-patients-with-different-types-of-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology